PONTE
VEDRA, Fla., Feb. 26,
2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc.,
(Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin,
a late-stage novel oral and reversible anticoagulant (blood
thinner) designed to prevent heart attacks, strokes and deaths due
to blood clots in patients with certain rare medical conditions,
today announced its participation at the upcoming Technology and
Heart Failure Therapeutics Conference (THT 2024), which is produced
by the Cardiovascular Research Foundation (CRF), taking place
March 4-6, 2024 in Boston.
THT 2024 offers a unique perspective by uniting device- and
technology-based therapies with drug-based approaches, effectively
bridging gaps in current practices. Attendees can expect
comprehensive updates on the status of treatments for heart
failure, spanning drug and device solutions, left ventricular
ejection fractions, and the latest pivotal studies yet to be
published or included in guidelines.
Quang Pham, Founder, Chairman and
Chief Executive Officer of Cadrenal Therapeutics, commented,
"Patients with cardiac implanted medical devices such as mechanical
heart valves (MHV) and left ventricular assist devices (LVADs)
require chronic anticoagulation (blood thinning) therapy.
Currently, warfarin (Coumadin), a Vitamin K Antagonist, remains the
only available medication despite its instability and diet
restrictions. We look forward to meeting with industry experts,
investigators, and innovators in cardiac implanted medical devices
at THT 2024 to discuss how tecarfarin can address unmet needs in
anticoagulation therapy."
Tecarfarin, a Vitamin K Antagonist, has orphan drug and fast
track designations from the FDA for the prevention of systemic
thromboembolism (blood clots) of cardiac origin in patients with
end-stage kidney disease (ESKD) and atrial fibrillation
(AFib). Cadrenal is also pursuing additional regulatory
strategies for unmet needs in anticoagulation therapy for patients
with left ventricular assist devices (LVADs) and those with
thrombotic antiphospholipid syndrome (APS).
Tecarfarin is specifically designed to leverage a different
metabolism pathway than the oldest and most commonly prescribed
Vitamin K Antagonist (warfarin). Tecarfarin has been evaluated in
eleven (11) human clinical trials and more than 1,000 individuals.
In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has
generally been well-tolerated in both healthy adult subjects and
patients with chronic kidney disease. Tecarfarin has also been
tested in patients with MHVs.
To schedule a meeting with Cadrenal at THT 2024, please email
press@cadrenal.com.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin for unmet needs
in anticoagulation therapy. Tecarfarin is a late-stage novel oral
and reversible anticoagulant (blood thinner) to prevent heart
attacks, strokes, and deaths due to blood clots in patients with
certain medical conditions. Tecarfarin has orphan drug and fast
track designations from the FDA for the prevention of systemic
thromboembolism (blood clots) of cardiac origin in patients with
end-stage kidney disease (ESKD) and atrial fibrillation (AFib).
Cadrenal is also pursuing additional regulatory strategies for
unmet needs in anticoagulation therapy for patients with left
ventricular assist devices (LVADs) and those with thrombotic
antiphospholipid syndrome (APS). Tecarfarin is specifically
designed to leverage a different metabolism pathway than the oldest
and most commonly prescribed Vitamin K Antagonist (warfarin).
Tecarfarin has been evaluated in eleven (11) human clinical trials
and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3
clinical trials, tecarfarin has generally been well-tolerated in
both healthy adult subjects and patients with chronic kidney
disease. For more information, please
visit: www.cadrenal.com.
Safe Harbor Statement
Any statements contained in this press release about future
expectations, plans, and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
"forward-looking statements." These statements include statements
regarding tecarfarin addressing unmet needs in anticoagulation
therapy. The words "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "will," "would" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including the ability of tecarfarin to
address unmet needs in anticoagulation therapy and obtain
regulatory approval to advance tecarfarin with patients with left
ventricular assist devices (LVADs), thrombotic APS and the other
risk factors described in the Company's Annual Report on Form 10-K
for the year ended December 31, 2022, and the Company's
subsequent filings with the SEC, including subsequent periodic
reports on Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K. Any forward-looking statements contained in this press
release speak only as of the date hereof and, except as required by
federal securities laws, the Company specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events, or otherwise.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-at-technology-and-heart-failure-therapeutics-tht-conference-302070595.html
SOURCE Cadrenal Therapeutics, Inc.